Australia’s active vaccine safety system

  • 18 Month Pertussis (whooping cough) vaccine safety surveillance data

    AusVaxSafety completed pertussis (whooping cough) booster vaccine safety active surveillance this month after nearly three years of monthly active surveillance. No safety signal was identified in children receiving DTPa at 18 months or DTPa-IPV at 4 years, with data contributed by over 55,000 participating parents/carers. Vaccine safety results are available on the AusVaxSafety website. The current reported event rates are consistent with existing data on pertussis vaccines. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

    Last updated 13/12/2019

    28,547 Parents/carers responded to an SMS about their child’s health a
    few days after their 18 month pertussis booster vaccinations.

    84%
    reported no adverse events

    84%
    reported no adverse events


    16%
    reported any adverse
    event, including...


    1.7%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    4,579 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.

  • 4 year Pertussis (whooping cough) vaccine safety surveillance data

    AusVaxSafety completed pertussis (whooping cough) booster vaccine safety active surveillance this month after nearly three years of monthly active surveillance. No safety signal was identified in children receiving DTPa at 18 months or DTPa-IPV at 4 years, with data contributed by over 55,000 participating parents/carers. Vaccine safety results are available on the AusVaxSafety website. The current reported event rates are consistent with existing data on pertussis vaccines. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

    Last updated 13/12/2019

    27,045 Parents/carers responded to an SMS about their child’s health a
    few days after their 4 year pertussis booster vaccinations.

    79.7%
    reported no adverse events

    79.7%
    reported no adverse events


    20.3%
    reported any adverse
    event, including...


    1.7%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    5,485 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.

  • 6 Months -< 5 years Influenza vaccine safety surveillance data

    Surveillance of 2020 influenza vaccine safety commenced from 9 April 2020. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

    Last updated 04/09/2020

    37,583 Parents/carers responded to an SMS about their child’s health a
    few days after their 2-month vaccinations.

    93.9%
    reported no adverse events

    93.9%
    reported no adverse events


    6.1%
    reported any adverse
    event, including...


    0.5%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    2,297 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.

  • 5-<18 years Influenza vaccine safety surveillance data

    Surveillance of 2020 influenza vaccine safety commenced from 9 April 2020. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

    Last updated 04/09/2020

    46,213 Parents/carers responded to an SMS about their child’s health a
    few days after their influenza vaccinations.

    95.8%
    reported no adverse events

    95.8%
    reported no adverse events


    4.2%
    reported any adverse
    event, including...


    0.2%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    1,956 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.

  • <2 years Meningococcal B vaccine safety surveillance data

    From July 2020 a meningococcal B vaccine, Bexsero®, is being funded under the National Immunisation Program for Aboriginal and Torres Strait Islander children at 2, 4, and 12 months of age (with a catch up program for Aboriginal and Torres Strait Islander children aged under 2 years until 30 June 2023), and people of all ages with specified medical risk conditions that increase their risk of invasive meningococcal disease. AusVaxSafety is monitoring the safety of Bexsero vaccine. The current reported event rates are consistent with what are expected according to the existing data.. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

    Last updated 11/12/2020

    4,179 Parents/carers responded to an SMS about their child’s health a
    few days after their vaccinations.

    82.3%
    reported no adverse events

    82.3%
    reported no adverse events


    17.7%
    reported any adverse
    event, including...


    1.4%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    739 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.

  • 2+ years Meningococcal B vaccine safety surveillance data

    From July 2020 a meningococcal B vaccine, Bexsero®, is being funded under the National Immunisation Program for Aboriginal and Torres Strait Islander children at 2, 4, and 12 months of age (with a catch up program for Aboriginal and Torres Strait Islander children aged under 2 years until 30 June 2023), and people of all ages with specified medical risk conditions that increase their risk of invasive meningococcal disease. AusVaxSafety is monitoring the safety of Bexsero vaccine. The current reported event rates are consistent with what are expected according to the existing data.. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

    Last updated 11/12/2020

    756 Parents/carers responded to an SMS about their child’s health a
    few days after their vaccinations.

    80.8%
    reported no adverse events

    80.8%
    reported no adverse events


    19.2%
    reported any adverse
    event, including...


    1.1%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    145 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.